TY - JOUR
T1 - Superior calcium bioavailability of effervescent potassium calcium citrate over tablet formulation of calcium citrate after Roux-en-Y gastric bypass
AU - Sakhaee, Khashayar
AU - Pak, Charles
PY - 2013/9
Y1 - 2013/9
N2 - Background: Calcium supplementation is commonly recommended for patients after Roux-en-Y gastric bypass to avert bone loss. To test the hypothesis that effervescent (liquid) potassium-calcium-citrate (PCC) might be more bioavailable than a tablet formulation of calcium citrate (Citracal Petite), the present study compared a single dose response of the 2 compounds. The present study was conducted at the University of Texas Southwestern Medical School at Dallas. Methods: A total of 15 patients who had undergone Roux-en-Y gastric bypass were included in a 2-phase, crossover, randomized study comparing the single-dose bioavailability of PCC versus Citracal Petite. After following a restricted diet for 1 week, the participants ingested either a single dose of 400 mg elemental calcium as PCC or Citracal Petite. Sequential serum and urine samples were collected for a 6-hour period after the dose and analyzed for calcium, parathyroid hormone, and acid-base parameters. Results: Compared with citracal petite, PCC significantly increased the serum calcium concentrations at 2, 3, and 4 hours after the oral load. The peak to baseline variation and increment in serum calcium (area under the curve) were significantly greater after PCC (P =.015 and P =.002, respectively). Concurrently, the baseline to nadir variation and decrement in serum parathyroid hormone (area over the curve) were significantly greater after PCC (P =.004 and P =.005, respectively). Moreover, compared with Citracal Petite, PCC caused a significantly greater increment in urinary citrate (P <.0001) and potassium (P =.0004) and a significantly lower increase in urinary ammonium (P =.045). Conclusion: In patients who have undergone Roux-en-Y gastric bypass, PCC was superior to Citracal Petite in conferring bioavailable calcium and suppressing parathyroid hormone secretion. PCC also provided an alkali load.
AB - Background: Calcium supplementation is commonly recommended for patients after Roux-en-Y gastric bypass to avert bone loss. To test the hypothesis that effervescent (liquid) potassium-calcium-citrate (PCC) might be more bioavailable than a tablet formulation of calcium citrate (Citracal Petite), the present study compared a single dose response of the 2 compounds. The present study was conducted at the University of Texas Southwestern Medical School at Dallas. Methods: A total of 15 patients who had undergone Roux-en-Y gastric bypass were included in a 2-phase, crossover, randomized study comparing the single-dose bioavailability of PCC versus Citracal Petite. After following a restricted diet for 1 week, the participants ingested either a single dose of 400 mg elemental calcium as PCC or Citracal Petite. Sequential serum and urine samples were collected for a 6-hour period after the dose and analyzed for calcium, parathyroid hormone, and acid-base parameters. Results: Compared with citracal petite, PCC significantly increased the serum calcium concentrations at 2, 3, and 4 hours after the oral load. The peak to baseline variation and increment in serum calcium (area under the curve) were significantly greater after PCC (P =.015 and P =.002, respectively). Concurrently, the baseline to nadir variation and decrement in serum parathyroid hormone (area over the curve) were significantly greater after PCC (P =.004 and P =.005, respectively). Moreover, compared with Citracal Petite, PCC caused a significantly greater increment in urinary citrate (P <.0001) and potassium (P =.0004) and a significantly lower increase in urinary ammonium (P =.045). Conclusion: In patients who have undergone Roux-en-Y gastric bypass, PCC was superior to Citracal Petite in conferring bioavailable calcium and suppressing parathyroid hormone secretion. PCC also provided an alkali load.
KW - Bariatric surgery
KW - Calcium bioavailability
KW - Nephrolithiasis
KW - Obesity
KW - Osteoporosis
KW - Potassium calcium citrate
UR - http://www.scopus.com/inward/record.url?scp=84885061301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885061301&partnerID=8YFLogxK
U2 - 10.1016/j.soard.2011.11.011
DO - 10.1016/j.soard.2011.11.011
M3 - Article
C2 - 22222299
AN - SCOPUS:84885061301
SN - 1550-7289
VL - 9
SP - 743
EP - 748
JO - Surgery for Obesity and Related Diseases
JF - Surgery for Obesity and Related Diseases
IS - 5
ER -